Skip to content

BioCytics

6 viewers · 30d

Total raised

$25K

+$25K this year

1 filing since 2026 · latest Options filed

Cumulative raised
LAST ROUND
Options · $25K
ROUNDS
1
INVESTORS
1
FOUNDED
N/A
HQ
Huntersville, NC
SECTOR
Biotechnology
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Biocytics is a biotechnology company specializing in the development of personalized cellular immunotherapies for cancer. It primarily focuses on autologous adaptive cell therapy (AACT) to treat solid tumors using a patient's own immune cells, while also operating as a contract development and manufacturing organization (CDMO) and contract research organization (CRO) for other early-phase cellular therapy firms.

What sets it apart

The company leverages an integrated model that combines its own therapeutic development with a full suite of services including a CDMO, CRO, and a BioBank. Its therapeutic platform is distinguished by a point-of-care manufacturing process for non-genetically modified effector cells.

Funding history

1 round
OptionsJan 2, 2026 · $25K min
Form D
+$25K$25K total

Latest SEC filings

via EDGAR · CIK 0001971839
Form D · Jan 2, 2026View on EDGAR

Products

1 tracked

Personalized Cellular Immunotherapies (AACT)

Cellular Immunotherapy

Biocytics develops autologous immune cellular therapies, such as its IND-bound BCyIF1 immune cell fractions, which are currently at the preclinical stage. This approach uses a patient's own reinvigorated immune cells, including γδ T-cells and other T-cells, to target and treat solid tumors without genetic modification.

  • Utilizes patient's own immune cells (autologous)
  • Focuses on non-genetically modified effector cells
  • Employs a point-of-care manufacturing process
  • Uses G-Rex-based optimization for scalable and affordable production

Links

WebsiteSEC EDGAR filings